Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody
- PMID: 6722005
- PMCID: PMC1976721
- DOI: 10.1038/bjc.1984.88
Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody
Abstract
Four patients with chronic lymphocytic leukaemia were treated by one or more infusions of polyclonal antibody specific for the immunoglobulin idiotype expressed on their leukaemic cells. The antibody was in the form of IgG from sheep antiserum. Three of the 4 cases showed a significant fall in blood lymphocyte count. On one occasion most of the residual circulating lymphocytes were apparently dead. However on all occasions the cell counts rebounded to near pre-infusion levels within one week. Viable lymphocytes recovered from the blood after infusion always showed evidence of antigenic modulation: a diminished level of surface idiotype in a patched distribution, with an accompanying refractoriness to lysis by anti-idiotype plus complement. When cultured in vitro blood lymphocytes from three of the four patients revealed an appreciable export of idiotypic Ig. These 3 patients showed plasma levels of idiotypic Ig up to 400 micrograms ml-1, reduced by plasma exchange prior to infusion. The fourth patient had a level of less than 4 micrograms ml-1, and was the only one in whom free antibody could be found in the plasma after infusion. These cases demonstrate two major factors which thwart antibody attack on leukaemic cells--extracellular antigen and antigenic modulation--as well as problems relating to sparseness of surface antigen, recruitment of effectors, and exhaustion of effectors.
Similar articles
-
Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces.Br J Cancer. 1980 Oct;42(4):495-502. doi: 10.1038/bjc.1980.271. Br J Cancer. 1980. PMID: 7192154 Free PMC article.
-
Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation.J Immunol. 1983 Feb;130(2):970-3. J Immunol. 1983. PMID: 6600259
-
Antibodies against urinary light chain idiotypes as agents for detection and destruction of human neoplastic B lymphocytes.J Immunol. 1983 Dec;131(6):3058-63. J Immunol. 1983. PMID: 6417240
-
BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor.Immunol Rev. 1979;48:81-106. doi: 10.1111/j.1600-065x.1979.tb00299.x. Immunol Rev. 1979. PMID: 94899 Review. No abstract available.
-
[Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].Zentralbl Gynakol. 1999;121(4):190-5. Zentralbl Gynakol. 1999. PMID: 10355096 Review. German.
Cited by
-
Achieving optimal outcomes in chronic lymphocytic leukaemia.Drugs. 2001;61(5):593-611. doi: 10.2165/00003495-200161050-00005. Drugs. 2001. PMID: 11368285 Review.
-
Cross-reactive variable-region associated epitopes of human IgG1 lambda paraprotein detected by a monoclonal antibody panel.Immunology. 1987 Jul;61(3):247-54. Immunology. 1987. PMID: 2440795 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical